- Home
- BATL vs SKYE Comparison
BATL vs SKYE Comparison
Compare BATL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BATL | SKYE |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 24.7M |
| IPO Year | 2004 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BATL | SKYE |
|---|---|---|
| Price | $1.58 | $0.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 12.4M | 122.6K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $166,043,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.57 |
| 52 Week High | $29.70 | $4.99 |
Technical Indicators
Market Signals| Indicator | BATL | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | 40.34 |
| Support Level | $1.06 | $0.57 |
| Resistance Level | $2.42 | $0.84 |
| Average True Range (ATR) | 0.25 | 0.04 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 32.66 | 47.29 |
Price Performance
Historical ComparisonAbout BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.